Plateletworks®: A Bedside Test to Monitor Clopidogrel Therapy in Healthy Cats
Plateletworks® is a bedside test used in human medicine to monitor platelet inhibiting drugs. As arterial thromboembolism is a common complication in cats suffering from cardiomyopathy, they are often treated with anti-platelet medication. Monitoring is may be important in such situations
The purpose of this prospective study was to determine if the Plateletworks® method can detect a decrease in platelet aggregation in cats receiving clopidogrel, an anti aggregating drug.
Nine sterilised healthy adult cats were used for this study. On day 1, a 2 ml venous blood sample was collected from the jugular vein. Immediately after blood collection, 1 ml was placed in the Plateletworks® baseline tube (EDTA), 1 ml was placed in the Plateletworks® ADP tube and a blood smear was prepared. Tubes were analyzed using a hematology impedance cell counter to determine platelet counts. Immediately following blood sampling, 18.75 mg of clopidogrel was administered orally to each cat once a day for three days. Venipuncture and blood analysis were repeated on day 4, in the same manner as on day 1. The percent platelet aggregation (PPA) was then calculated as follows:
PPA on day 1 (mean ± SD) was calculated as 70.55 ± 15.59 % and on day 4 was 1.52 ± 9.5 %. Clopidogrel therapy caused a marked decrease in PPA (P<0.01).
The Plateletworks® method appears to be a promising test to monitor clopidogrel therapy in cats.